Rhenman & Partners Asset Management Ab Sage Therapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $3.53 Million - $5.26 Million	-115,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $1.61 Million - $2.29 Million	40,000 Added 53.33%	115,000 $5.1 Million
Q2 2021 Aug 13, 2021	BUY	$54.88 - $79.29 $4.12 Million - $5.95 Million	75,000 New	75,000 $4.26 Million
Q2 2020 Jul 16, 2020	SELL	$25.95 - $43.15 $1.3 Million - $2.16 Million	-50,000 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$60.18 - $154.77 $1.81 Million - $4.64 Million	30,000 Added 150.0%	50,000 $3.61 Million
Q3 2019 Oct 16, 2019	SELL	$140.29 - $189.96 $229,935 - $311,344	-1,639 Reduced 7.57%	20,000 $2.81 Million
Q2 2019 Jul 22, 2019	SELL	$157.85 - $183.09 $4.74 Million - $5.49 Million	-30,000 Reduced 58.1%	21,639 $3.96 Million
Q1 2019 Apr 11, 2019	SELL	$89.33 - $163.65 $7.66 Million - $14 Million	-85,700 Reduced 62.4%	51,639 $8.21 Million
Q4 2018 Feb 05, 2019	BUY	$81.94 - $139.71 $1.03 Million - $1.76 Million	12,600 Added 10.1%	137,339 $13.2 Million
Q3 2018 Oct 03, 2018	SELL	$138.11 - $169.04 $682,263 - $835,057	-4,940 Reduced 3.81%	124,739 $17.6 Million
Q2 2018 Jul 20, 2018	BUY	$140.36 - $175.76 $4.87 Million - $6.1 Million	34,679 Added 36.5%	129,679 $20.3 Million
Q1 2018 Apr 11, 2018	SELL	$152.15 - $192.33 $1.51 Million - $1.91 Million	-9,930 Reduced 9.46%	95,000 $15.3 Million
Q4 2017 Jan 19, 2018	BUY	$60.72 - $167.34 $3.34 Million - $9.19 Million	54,930 Added 109.86%	104,930 $17.3 Million
Q3 2017 Oct 13, 2017	BUY	$61.4 - $88.52 $3.07 Million - $4.43 Million	50,000	50,000 $3.12 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $318M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account